RxDoctor Payments Data

Veronica Zavala-Carraway, PA

Physician Assistant · Houston, TXNPI 1184998197

Payments from drug & device makers

$1,350in general payments, 2019–2025

Across 61 payments — averaging $22.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$356
  • AstraZeneca$355
  • Novo Nordisk$339
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$133
  • Amgen$68
  • Boehringer Ingelheim$41
  • plus $58 from 2 others

What the payments were for

  • Food & beverage$1,350100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,350 in reported general payments places this provider in the 70th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$3,517
Medicare patients
26
Services billed
68

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin12$20,238
FarxigaDapagliflozin Propanediol19$17,322
OzempicSemaglutide14$14,457
Wixela InhubFluticasone Propion/Salmeterol19$3,183
Albuterol Sulfate HfaAlbuterol Sulfate42$1,902
Rosuvastatin Calcium52$1,249
Atorvastatin Calcium97$1,059
Losartan Potassium35$409
Nifedipine ErNifedipine18$400
Levothyroxine Sodium34$383
Montelukast Sodium25$362
Metformin Hcl46$357
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide20$344
Glipizide ErGlipizide22$282
Lisinopril34$271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$41$20,23812 claims
AstraZenecaFarxiga$355$17,32219 claims
Novo NordiskOzempic$339$14,45714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →